Oligomerix

Oligomerix is a highly differentiated biopharmaceutical company discovering and developing novel therapeutics for Alzheimer’s disease and related neurodegenerative diseases characterized by tau protein aggregation. It has developed two highly differentiated approaches for small molecule drug discovery: tau oligomer inhibitor program and tau protease inhibitor program.

Each approach has its own associated biomarkers programs. These are enabling and accelerating technologies for large pharmaceutical licensees, partners and acquirers that will play a major role in successfully intervening in this costly, debilitating disease.